Thyrocare Tech. Q2 FY27 Earnings Call — Analysis (NSE: THYROCARE)

Thyrocare delivered 25% YoY consolidated revenue growth in Q2FY27 with 33% EBITDA margins on 27% pathology volume expansion, while initiating the divestment of its low-ROCE radiology subsidiary for ₹141 Cr.

2 Nov 2026 · Analysis by Alpha Inflection

Result quality: stable — Results context unavailable. Management sentiment: optimistic.

The take

Q2FY27 Consolidated Revenue ₹271 Cr ( +25% YoY ) . Guidance raised — Q3 FY27 q3 fy27 product launch expenses ₹3 Cr . New story: Franchisee network scaling .

Results

Consolidated revenue grew 25% YoY to ₹271 Cr, gross margins expanded 190bps YoY to 74.2%, and pre-exceptional PAT rose 26% YoY to ₹60 Cr.

Financial highlights

Guidance

Management upgraded full-year FY27 revenue growth expectations to early 20s% and targeted specialty diagnostics to contribute 10-15% of revenue over 3-5 years.

What management committed to

• Thyrocare expects to maintain annual net franchisee additions in the range of 1,500 to 2,000 per year going forward, sustaining the growth trajectory of the base. — 1,500 to 2,000, FY28 onwards
• Management expects to invest approximately INR30 crores in capex in H2 FY27 for lab expansion and growth capacity, consistent with the H1 run-rate. — INR30 crores, H2 FY27
• Management guided that the normalized long-term EBITDA margin will anchor in the range of 31% to 31.5% as operating leverage is reinvested into growth initiatives. — 31% to 31.5%, FY28 onwards
• Management expects to incur approximately INR3 crores in product launch expenses in Q3 FY27 for the pregnancy kit and related D2C initiatives. — INR3 crores, Q3 FY27

Key themes

Pathology volume acceleration and capital reallocation

How the narrative shifted

• Franchisee network scaling: The narrative shifted from confident scaling to a verified high-volume engine, though the CEO tempered Q3 expectations against the CCO's momentum claims.
• Specialty diagnostics foray: The target range was softened from 15-20% to 10-15%, positioning the initial portfolio (allergy/genomics/NIPT) as a deliberate, credibility-first build rather than a volume push.
• Affordable diagnostics mission: Reiterated as the foundational value driver that shapes all expansion, from franchisee adoption to the pregnancy kit's lab-confirmation value prop.
• Radiology divestment and capital discipline: The narrative pivoted from strategic rationale for exiting to concrete deal execution, with detailed impairment accounting that reinforced the capital discipline thesis.
• Parent company deleveraging: The timeline was materially improved from Q2FY28 to Q4FY27, giving a clearer and faster path to a potential IPO or reverse merger.
• Digital and operational excellence: Operational metrics showcased as proof of quality at scale: 3.5-hour TAT, 2.9 complaints per million, 96% NABL processing, and 99% on-time phlebotomy supporting franchise recruitment.
• D2C and point-of-care product strategy: Launched a pregnancy test kit with a unique lab-confirmation coupon, leveraging the group's distribution network (Ascent) to reach 10,000+ chemists, positioned as a lead-gen funnel for core lab business.
• Revenue per patient and test bundling: Strategic focus on increasing tests per patient (up 12%) through bundling, improving profitability at the patient level given fixed collection and logistics costs.
• Geographical expansion and Africa foray: Opened labs in 4 new Tier 2/3 Indian cities and a hybrid lab in Jamshedpur; a lab in Tanzania was established, announced alongside a foray-into-Africa narrative.

Operational commentary

• Initiated divestment of radiology business Nueclear Healthcare Limited (NHL) for ₹141 Cr (₹81.9 Cr cash and ₹59.5 Cr equity in Trovera) to exit a 6.95% ROCE drag and refocus on high-ROCE pathology (34.9% ROCE).
• Added 1,180 net active franchisees in Q2FY27 (highest in 3 years), expanding active franchisee base to 12,911 (+27% YoY revenue growth in franchisee segment).
• Expanded laboratory footprint to 49 labs (48 in India, 1 in Tanzania) with 5 new labs added in Q2 (Asansol, Nashik, Madurai, Jabalpur, Jamshedpur), bringing testing within 150 km across most of India.
• Specialty diagnostics (reproductive genomics/NIPT and allergy) commercially live, currently contributing ~4% of pathology revenue.
• Launched consumer point-of-care pregnancy test kit at ₹60 MRP with bundled ₹399 beta-hCG lab test coupon, leveraging API Group's Ascent distribution across 10,000+ pharmacies.
• Reduced test turnaround time to 3.5 hours on average, and complaint rates reached Six Sigma levels at 2.9 per million tests.

Analyst Q&A

• Q. Will elevated franchisee additions (>1,100/quarter) continue as a normalized run-rate?

  Management cautioned that Q3 is historically a slow season for franchisee additions, expecting normalized additions to resume in Q4, though full-year additions will exceed the 1,500 target.

• Q. What is the status and rationale of a potential reverse merger or merger between API Group and Thyrocare?

  Management stated discussions are premature until API Group ex-Thyrocare turns profitable (guided by Q4 FY27); no corporate action will be evaluated before that milestone.

• Q. Why did management take an impairment on NHL when sale consideration exceeds net worth?

  CFO explained that impairment reflects the gap between carrying investment value in books (₹180 Cr including consolidated goodwill) and sale consideration (₹141 Cr), not standalone net worth.

• Q. How will margin trajectory behave given marketing and field force investments in specialty and D2C test kits?

  Management guided that operating leverage from 25% revenue growth will be reinvested into growth initiatives, anchoring long-term EBITDA margins at 31.0%-31.5%.

View source

Research and educational content only. Not investment advice.